Publications by authors named "Valentina Fustaino"

Sarcomas are rare, mesenchymal tumors, representing about 10-15% of all childhood cancers. GD2 is a suitable target for chimeric antigen receptor (CAR) T-cell therapy due to its overexpression in several solid tumors. In this preclinical study, we investigated the potential use of iCasp9.

View Article and Find Full Text PDF

We investigated mRNA-lncRNA co-expression patterns in a cellular model system of non-small cell lung cancer (NSCLC) sensitive and resistant to the epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) erlotinib/gefitinib. The aim of this study was to unveil insights into the complex mechanisms of NSCLC targeted therapy resistance and epithelial-to-mesenchymal transition (EMT). Genome-wide RNA expression was quantified for weighted gene co-expression network analysis (WGCNA) to correlate the expression levels of mRNAs and lncRNAs.

View Article and Find Full Text PDF
Article Synopsis
  • Phosphodiesterase 2A (Pde2A) helps break down important molecules called cAMP and cGMP that are needed for heart health.
  • When Pde2A doesn't work right, it can lead to heart problems in baby mice, which are called congenital heart defects (CHDs).
  • Using medicines like Metoprolol and Sildenafil can help fix some of these heart problems by balancing cAMP and cGMP levels and reducing stress on the heart.
View Article and Find Full Text PDF

Background: Lung cancer remains the leading cause of cancer-related death worldwide. Targeted therapies with tyrosine kinase inhibitors (TKIs) result in improvement in survival for non-small cell lung cancer (NSCLC) with activating mutations of the epidermal growth factor receptor (EGFR). Unfortunately, most patients who initially respond to EGFR-TKI ultimately develop resistance to therapy, resulting in cancer progression and relapse.

View Article and Find Full Text PDF

Schistosomiasis is a neglected tropical disease caused by parasitic flatworms (blood fluke) of the genus Schistosoma. Parasites acquire most nutrients for their development and sustainment within the definitive host either by ingestion into the gut or across the body surface. Over the years, the best conditions for long-term maintenance of parasites in vitro have been thoroughly established.

View Article and Find Full Text PDF

Schistosomiasis is one of the most devastating neglected tropical parasitic diseases caused by trematodes of the genus Schistosoma. Praziquantel (PZQ) is today the only drug used in humans and animals for the treatment of schistosomiasis but unfortunately it is poorly effective on larval and juvenile stages of the parasite. Therefore, it is urgent the discovery of new drug targets and compounds.

View Article and Find Full Text PDF

Endothelial cells senescence is a physiological process affecting vascular integrity. It can contribute to heart and arterial stiffening and remodeling, impaired angiogenesis, defective vascular repair, and with an increasing prevalence of atherosclerosis. Drugs used as antineoplastic therapies, targeting tumor as well as endothelial cells, can also trigger endothelial cells senescence.

View Article and Find Full Text PDF

Inflammatory caspases, including human caspase-4 (CASP4), play key roles in innate immune responses to promote fusion of phagosomes harboring pathogenic bacteria with lysosomes, halt intracellular replication of pathogens, maturation and secretion of pro-inflammatory cytokines. The role of inflammatory caspases in cancer cells remains poorly investigated. Here, we explored the consequences of modulating CASP4 expression levels on the migratory behavior of epithelial cancer cell lines.

View Article and Find Full Text PDF

Increasing evidence points to a key role played by epithelial-mesenchymal transition (EMT) in cancer progression and drug resistance. In this study, we used and approaches to investigate whether EMT phenotypes are associated to resistance to target therapy in a non-small cell lung cancer model system harboring activating mutations of the epidermal growth factor receptor. The combination of different analysis techniques allowed us to describe intermediate/hybrid and complete EMT phenotypes respectively in HCC827- and HCC4006-derived drug-resistant human cancer cell lines.

View Article and Find Full Text PDF
Article Synopsis
  • EGFR is a crucial protein in regulating cell behaviors and is linked to various cancers, making its inhibition a key focus in cancer treatment, particularly for lung, breast, and ovarian cancers.
  • In non-small cell lung cancers (NSCLC) with EGFR mutations, treatments using tyrosine kinase inhibitors (TKIs) can initially shrink tumors, but resistance often develops due to genetic mutations or alternative signaling pathways.
  • Research has established NSCLC cell lines resistant to EGFR TKIs, revealing that resistance may be linked to changes in EGFR gene amplification and increased activation of other receptors, prompting studies on the potential of combining MET and EGFR inhibitors for better treatment outcomes.
View Article and Find Full Text PDF